KEGG   DRUG: Fidanacogene elaparvovec
Entry
D12908                      Drug                                   
Name
Fidanacogene elaparvovec (USAN/INN);
Fidanacogene elaparvovec-dzkt;
Beqvez (TN)
Class
Blood modifier agent
 DG02016  Hemostatics
  DG02014  Blood coagulation accelerant
   DG02013  Blood coagulation factor
Remark
ATC code: B02BD17
Efficacy
Bleeding suppressant
  Disease
Hemophilia B, congenital factor IX deficiency [DS:H00219]
  Type
Gene therapy product
Comment
Recombinant adeno-associated virus vector, Spark100, containing the human blood- coagulation factor IX padua variant gene
Treatment of hemophilia B
Target
F9* [HSA_VAR:2158v1] [HSA:2158] [KO:K01321]
  Pathway
hsa04610  Complement and coagulation cascades
  Network
nt06514  Coagulation cascade
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 B BLOOD AND BLOOD FORMING ORGANS
  B02 ANTIHEMORRHAGICS
   B02B VITAMIN K AND OTHER HEMOSTATICS
    B02BD Blood coagulation factors
     B02BD17 Fidanacogene elaparvovec
      D12908  Fidanacogene elaparvovec (USAN/INN)
Drug groups [BR:br08330]
 Blood modifier agent
  DG02016  Hemostatics
   DG02014  Blood coagulation accelerant
    DG02013  Blood coagulation factor
     D12908  Fidanacogene elaparvovec
Target-based classification of drugs [BR:br08310]
 Peptidases and inhibitors
  Serine peptidases
   Chymotrypsin family
    F9* [HSA_VAR:2158v1]
     D12908  Fidanacogene elaparvovec (USAN/INN)
New drug approvals in the USA [br08319.html]
 Cellular and gene therapy products
  D12908
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D12908
 Cellular and gene therapy products
  D12908
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D12908
Other DBs
CAS: 1954659-47-2
PubChem: 497621321
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system